目的：评估由雷珠单抗转为康柏西普治疗的年龄相关性黄斑变性(ARMD)患者治疗后视功能及生活质量情况。

方法：选取2016-01/2017-08我院收治的因雷珠单抗治疗疗效不佳转为康柏西普治疗的新生血管性ARMD患者20例29眼，比较行玻璃体腔注射康柏西普治疗前和治疗第4mo患者最佳矫正视力(BCVA)、对比敏感度(CS)、中央视网膜厚度(CRT)及生活质量评分情况。

结果：治疗第4mo，患者BCVA较治疗前改善，差异有统计学意义(P<0.05)； OCT检测CRT较治疗前降低，差异有统计学意义(P<0.05)； 各空间频率CS均较治疗前改善，差异均有统计学意义(P<0.05)； NEI VFQ-25评分总分及各项目评分均较治疗前提高，差异均有统计学意义(P<0.05)

结论：玻璃体腔注射康柏西普治疗ARMD可明显改善患者的视功能和生活质量。

METHODS: Twenty patients(29 eyes)with angiogenic ARMD who were treated in our hospital in January 2016 to August 2017 because of the poor therapeutic effect of ranibizumab were selected. The main outcome measures were BCVA, contrast sensitivity(CS), mean changes of central retinal thickness(CRT)and 25 visual function questionnaires(NEI VFQ-25)from baseline to 4mo. The statistical data were analyzed by paired t test to compare the mean values of continuous variables.

RESULTS: At 4mo after treatment, BCVA were significantly improved compared to before treatment(P<0.05). The CRT detected by OCT decreased(P<0.05). CS at different frequency was better than before treatment(P<0.05). NEI VFQ-25 scores were higher than before treatment(P<0.05).

CONCLUSION: In the treatment of age-related macular degeneration with conbercept, the visual function and the quality of life are remarkably improved.